Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
7
100%

Phase Distribution

0

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
7(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 7 finished

Non-Completion Rate

100.0%

7 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Terminated(7)

Detailed Status

Withdrawn7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 27 (100.0%)

Trials by Status

withdrawn7100%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_2

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

NCT00003455
withdrawnphase_2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003517
withdrawnphase_2

Antineoplaston Therapy in Treating Patients With Colon Cancer

NCT00003486
withdrawnphase_2

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

NCT00003536
withdrawnphase_2

Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00003505
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00003455Phase 2

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Withdrawn
NCT00003517Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Withdrawn
NCT00003486Phase 2

Antineoplaston Therapy in Treating Patients With Colon Cancer

Withdrawn
NCT00003536Phase 2

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

Withdrawn
NCT00003505Phase 2

Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Withdrawn
NCT00003514Phase 2

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Withdrawn
NCT00003502Phase 2

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
7